Penumbra
PEN
Market cap $9.93B

256.50 USD

+3.10

1.22%

At close Jun 13, 4:00 PM EDT

After hours

256.50

+0.00

0.00%

1 day

1.22%

5 days

-0.95%

1 month

-13.36%

3 months

-1.58%

6 months

4.46%

Year to date

6.88%

1 year

36.44%

5 years

48.70%

10 years

521.07%

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

502% more call options, than puts

Call options by funds: $95.8M | Put options by funds: $15.9M

136% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 39

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

13% more funds holding

Funds holding: 367 [Q4 2024] → 415 (+48) [Q1 2025]

11% more capital invested

Capital invested by funds: $8.3B [Q4 2024] → $9.24B (+$945M) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 129

1.28% less ownership

Funds ownership: 90.97% [Q4 2024] → 89.69% (-1.28%) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$315

23%

upside

Avg. target

$325

27%

upside

High target

$330

29%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Shagun Singh	29%upside $330	Outperform Maintained	24 Apr 2025
UBS Priya Sachdeva	29%upside $330	Buy Maintained	24 Apr 2025
Truist Securities David Rescott	29%upside $330	Buy Maintained	24 Apr 2025
Stifel Mathew Blackman	24%upside $318	Buy Maintained	24 Apr 2025
Wells Fargo Larry Biegelsen	23%upside $315	Overweight Maintained	24 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about PEN published over the past 30 days

Zacks Investment Research

ITGR or PEN: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

ITGR or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.

Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Zacks Investment Research

PEN Stock Rises Following the Launch of Ruby XL System

Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.

PEN Stock Rises Following the Launch of Ruby XL System

Zacks Investment Research

3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom

PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.

3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

ALAMEDA, Calif. , June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi.

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Zacks Investment Research

Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?

Zacks Investment Research

Penumbra Rallies 35.9% in a Year: What's Driving the Stock?

PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.

Penumbra Rallies 35.9% in a Year: What's Driving the Stock?

Penumbra, Inc. to Present at Upcoming Investor Conferences

ALAMEDA, Calif. , May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.

Penumbra, Inc. to Present at Upcoming Investor Conferences

Zacks Investment Research

Here's Why Penumbra (PEN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Penumbra (PEN) is a Strong Momentum Stock

Zacks Investment Research

Here's Why Penumbra (PEN) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Penumbra (PEN) is a Strong Growth Stock

See News Rankings

Charts implemented using Lightweight Charts™